Browse > Article
http://dx.doi.org/10.4062/biomolther.2016.168

Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90  

Jun, Kyu-Yeon (College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University)
Kwon, Youngjoo (College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University)
Publication Information
Biomolecules & Therapeutics / v.24, no.5, 2016 , pp. 453-468 More about this Journal
Abstract
There is a conserved ATPase domain in topoisomerase II (topo II) and heat shock protein 90 (Hsp90) which belong to the GHKL (gyrase, Hsp90, histidine kinase, and MutL) family. The inhibitors that target each of topo II and Hsp90 are intensively studied as anti-cancer drugs since they play very important roles in cell proliferation and survival. Therefore the development of dual targeting anti-cancer drugs for topo II and Hsp90 is suggested to be a promising area. The topo II and Hsp90 inhibitors, known to bind to their ATP binding site, were searched. All the inhibitors investigated were docked to both topo II and Hsp90. Four candidate compounds as possible dual inhibitors were selected by analyzing the molecular docking study. The pharmacophore model of dual inhibitors for topo II and Hsp90 were generated and the design of novel dual inhibitor was proposed.
Keywords
Topoisomerase II; Heat shock protein 90; Molecular docking study; Design of dual inhibitor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Agatsuma, T., Ogawa, H., Akasaka, K., Asai, A., Yamashita, Y., Mizukami, T., Akinaga, S. and Saitoh, Y. (2002) Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities. Bioorg. Med. Chem. 10, 3445-3454.   DOI
2 Barker, C. R., Hamlett, J., Pennington, S. R., Burrows, F., Lundgren, K., Lough, R., Watson, A. J. and Jenkins, J. R. (2006) The topoisomerase II-Hsp90 complex: A new chemotherapeutic target? Int. J. Cancer 118, 2685-2693.   DOI
3 Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L. and Rosen, N. (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8, 289-299.   DOI
4 Dutta Gupta, S., Snigdha, D., Mazaira, G. I., Galigniana, M. D., Subrahmanyam, C. V., Gowrishankar, N. L. and Raghavendra, N. M. (2014) Molecular docking study, synthesis and biological evaluation of schiff bases as Hsp90 inhibitors. Biomed. Pharmacother. 68, 369-376.   DOI
5 Dutta, R. and Inouye, M. (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25, 24-28.   DOI
6 Furet, P., Schoepfer, J., Radimerski, T. and Chene, P. (2009) Discovery of a new class of catalytic topoisomerase II inhibitors targeting the atp-binding site by structure based design. Part I. Bioorg. Med. Chem. Lett. 19, 4014-4017.   DOI
7 Gui, M., Shi, D. K., Huang, M., Zhao, Y., Sun, Q. M., Zhang, J., Chen, Q., Feng, J. M., Liu, C. H., Li, M., Li, Y. X., Geng, M. and Ding, J. (2011) D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase $II{\alpha}$. Invest. New Drugs 29, 800-810.   DOI
8 Hall, T. A. (1999) BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/nt. Nucl. Acids Symp. Ser. 41, 95-98.
9 Hu, C. X., Zuo, Z. L., Xiong, B., Ma, J. G., Geng, M. Y., Lin, L. P., Jiang, H. L. and Ding, J. (2006) Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol. Pharmacol. 70, 1593-1601.   DOI
10 Huang, H., Chen, Q., Ku, X., Meng, L., Lin, L., Wang, X., Zhu, C., Wang, Y., Chen, Z., Li, M., Jiang, H., Chen, K., Ding, J. and Liu, H. (2010) A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase iialpha catalytic activity. J. Med. Chem. 53, 3048-3064.   DOI
11 Ikuina, Y., Amishiro, N., Miyata, M., Narumi, H., Ogawa, H., Akiyama, T., Shiotsu, Y., Akinaga, S. and Murakata, C. (2003) Synthesis and antitumor activity of novel o-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 46, 2534-2541.   DOI
12 Jain, A. N. (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46, 499-511.   DOI
13 Jensen, L. H., Liang, H., Shoemaker, R., Grauslund, M., Sehested, M. and Hasinoff, B. B. (2006) A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol. Pharmacol. 70, 1503-1513.   DOI
14 Jensen, L. H., Thougaard, A. V., Grauslund, M., Sokilde, B., Carstensen, E. V., Dvinge, H. K., Scudiero, D. A., Jensen, P. B., Shoemaker, R. H. and Sehested, M. (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 65, 7470-7477.   DOI
15 Jez, J. M., Chen, J. C., Rastelli, G., Stroud, R. M. and Santi, D. V. (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem. Biol. 10, 361-368.   DOI
16 Jimenez-Alonso, S., Orellana, H. C., Estevez-Braun, A., Ravelo, A. G., Perez-Sacau, E. and Machin, F. (2008) Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors. J. Med. Chem. 51, 6761-6772.   DOI
17 Kung, P. P., Funk, L., Meng, J., Collins, M., Zhou, J. Z., Johnson, M. C., Ekker, A., Wang, J., Mehta, P., Yin, M. J., Rodgers, C., Davies, J. F., 2nd, Bayman, E., Smeal, T., Maegley, K. A. and Gehring, M. R. (2008) Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 18, 6273-6278.   DOI
18 Jun, K. Y., Lee, E. Y., Jung, M. J., Lee, O. H., Lee, E. S., Park Choo, H. Y., Na, Y. and Kwon, Y. (2011) Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase $II{\alpha}$ catalytic inhibitor. Eur. J. Med. Chem. 46, 1964-1971.   DOI
19 Kang, K., Nho, C. W., Kim, N. D., Song, D. G., Park, Y. G., Kim, M., Pan, C. H., Shin, D., Oh, S. H. and Oh, H. S. (2014) Daurinol, a catalytic inhibitor of topoisomerase $II{\alpha}$, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int. J. Oncol. 45, 558-566.   DOI
20 Kreusch, A., Han, S., Brinker, A., Zhou, V., Choi, H. S., He, Y., Lesley, S. A., Caldwell, J. and Gu, X. J. (2005) Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 15, 1475-1478.   DOI
21 Li, P. H., Zeng, P., Chen, S. B., Yao, P. F., Mai, Y. W., Tan, J. H., Ou, T. M., Huang, S. L., Li, D., Gu, L. Q. and Huang, Z. S. (2016) Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors. J. Med. Chem. 59, 238-252.   DOI
22 Li, Y., Luan, Y., Qi, X., Li, M., Gong, L., Xue, X., Wu, X., Wu, Y., Chen, M., Xing, G., Yao, J. and Ren, J. (2010) Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting atp hydrolysis of topoisomerase II. Toxicol. Sci. 118, 435-443.   DOI
23 Moulin, E., Zoete, V., Barluenga, S., Karplus, M. and Winssinger, N. (2005b) Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. J. Am. Chem. Soc. 127, 6999-7004.   DOI
24 Liang, J., Edelsbrunner, H. and Woodward, C. (1998) Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci. 7, 1884-1897.   DOI
25 Ma, Y., Wang, J. G., Wang, B. and Li, Z. M. (2011) Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic ${\alpha}$-aminophosphonates that act as novel topoisomerase II inhibitors. J. Mol. Model. 17, 1899-1909.   DOI
26 Moulin, E., Barluenga, S. and Winssinger, N. (2005a) Concise synthesis of pochonin A, an HSP90 inhibitor. Org. Lett. 7, 5637-5639.   DOI
27 Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., Graham, B., McMenamin, R., O'Brien, M. A., Patel, S., Phillips, T. R., Williams, G., Woodhead, A. J. and Woolford, A. J. (2010) Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem. 53, 5942-5955.   DOI
28 Neckers, L. (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55-S61.   DOI
29 Nitiss, J. L. (2009a) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338-350.   DOI
30 Nitiss, J. L. (2009b) DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 9, 327-337.   DOI
31 Pogorelcnik, B., Perdih, A. and Solmajer, T. (2013) Recent advances in the development of catalytic inhibitors of human DNA topoisomerase $II{\alpha}$ as novel anticancer agents. Curr. Med. Chem. 20, 694-709.   DOI
32 Park, S. E., Chang, I. H., Jun, K. Y., Lee, E., Lee, E. S., Na, Y. and Kwon, Y. (2013) 3-(3-butylamino-2-hydroxy-propoxy)-1-hydroxyxanthen-9-one acts as a topoisomerase $II{\alpha}$ catalytic inhibitor with low DNA damage. Eur. J. Med. Chem. 69, 139-145.   DOI
33 Patel, K., Piagentini, M., Rascher, A., Tian, Z. Q., Buchanan, G. O., Regentin, R., Hu, Z., Hutchinson, C. R. and McDaniel, R. (2004) Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem. Biol. 11, 1625-1633.   DOI
34 Petrelli, A. and Giordano, S. (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422-432.   DOI
35 Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T. and McLean, P. J. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332, 849-857.   DOI
36 Qin, Y., Meng, L., Hu, C., Duan, W., Zuo, Z., Lin, L., Zhang, X. and Ding, J. (2007) Gambogic acid inhibits the catalytic activity of human topoisomerase $II{\alpha}$ by binding to its ATPase domain. Mol. Cancer Ther. 6, 2429-2440.   DOI
37 Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W. and Pearl, L. H. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266.   DOI
38 Sidera, K. and Patsavoudi, E. (2014) HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat. Anticancer Drug Discov. 9, 1-20.
39 Rowlands, M. G., Newbatt, Y. M., Prodromou, C., Pearl, L. H., Workman, P. and Aherne, W. (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327, 176-183.   DOI
40 Schulte, T. W. and Neckers, L. M. (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42, 273-279.   DOI
41 Soga, S., Neckers, L. M., Schulte, T. W., Shiotsu, Y., Akasaka, K., Narumi, H., Agatsuma, T., Ikuina, Y., Murakata, C., Tamaoki, T. and Akinaga, S. (1999) KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 59, 2931-2938.
42 Soga, S., Sharma, S. V., Shiotsu, Y., Shimizu, M., Tahara, H., Yamaguchi, K., Ikuina, Y., Murakata, C., Tamaoki, T., Kurebayashi, J., Schulte, T. W., Neckers, L. M. and Akinaga, S. (2001) Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother. Pharmacol. 48, 435-445.   DOI
43 Wang, B., Miao, Z. W., Wang, J., Chen, R. Y. and Zhang, X. D. (2008) Synthesis and biological evaluation of novel naphthoquinone fused cyclic aminoalkylphosphonates and aminoalkylphosphonic monoester. Amino Acids 35, 463-468.   DOI
44 Wang, P., Leung, C. H., Ma, D. L., Lu, W. and Che, C. M. (2010) Organoplatinum(II) complexes with nucleobase motifs as inhibitors of human topoisomerase II catalytic activity. Chem. Asian J. 5, 2271-2280.   DOI
45 Wei, H., Ruthenburg, A. J., Bechis, S. K. and Verdine, G. L. (2005) Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J. Biol. Chem. 280, 37041-37047.   DOI
46 Yao, Q., Weigel, B. and Kersey, J. (2007) Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin. Cancer Res. 13, 1591-1600.   DOI
47 Xu, X. L., Bao, Q. C., Jia, J. M., Liu, F., Guo, X. K., Zhang, M. Y., Wei, J. L., Lu, M. C., Xu, L. L., Zhang, X. J., You, Q. D. and Sun, H. P. (2016) CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Sci. Rep. 6, 19004.   DOI
48 Yang, S. Y., Jia, X. Z., Feng, L. Y., Li, S. Y., An, G. S., Ni, J. H. and Jia, H. T. (2009) Inhibition of topoisomerase ii by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol. 77, 433-443.   DOI
49 Yang, Z. Q., Geng, X., Solit, D., Pratilas, C. A., Rosen, N. and Danishefsky, S. J. (2004) New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc. 126, 7881-7889.   DOI
50 Basarab, G. S., Kern, G. H., McNulty, J., Mueller, J. P., Lawrence, K., Vishwanathan, K., Alm, R. A., Barvian, K., Doig, P., Galullo, V., Gardner, H., Gowravaram, M., Huband, M., Kimzey, A., Morningstar, M., Kutschke, A., Lahiri, S. D., Perros, M., Singh, R., Schuck, V. J., Tommasi, R., Walkup, G. and Newman, J. V. (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-inclass agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep. 5, 11827.   DOI
51 Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C. and Bharatam, P. V. (2011) N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase $II{\alpha}$ and induce apoptosis in G1/S phase. J. Med. Chem. 54, 5013-5030.   DOI
52 Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K. M., Collins, I., Davies, N. G., Drysdale, M. J., Dymock, B., Eccles, S. A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R. E., James, K., Jordan, A. M., Lockie, A., Martins, V., Massey, A., Matthews, T. P., McDonald, E., Northfield, C. J., Pearl, L. H., Prodromou, C., Ray, S., Raynaud, F. I., Roughley, S. D., Sharp, S. Y., Surgenor, A., Walmsley, D. L., Webb, P., Wood, M., Workman, P. and Wright, L. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51, 196-218.   DOI
53 Chene, P. (2002) ATPases as drug targets: Learning from their structure. Nat. Rev. Drug Discov. 1, 665-673.   DOI
54 Chene, P., Rudloff, J., Schoepfer, J., Furet, P., Meier, P., Qian, Z., Schlaeppi, J. M., Schmitz, R. and Radimerski, T. (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATPcompetitive purine analogue. BMC Chem. Biol. 9, 1.   DOI